SCHEMBL25930932

SCHEMBL25930932

CCc1ccc(NC(=O)c2ccc3c(c2)N(C)C(=O)CS3)cc1S(=O)(=O)N1CCCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 13/20 0.52
▸ SMN1; SMN2 Q16637 5/20 0.52
▸ HTT P42858 4/20 0.52
▸ MEN1 O00255 3/20 0.52
▸ KMT2A Q03164 3/20 0.52
▸ OPRM1 P35372 1/20 0.52
▸ OPRD1 P41143 1/20 0.52
▸ ESR1 P03372 1/20 0.49
▸ ESR2 Q92731 1/20 0.49
▸ MAPK1 P28482 5/20 0.48
▸ LMNA P02545 3/20 0.48
▸ TP53 P04637 3/20 0.48
▸ CNR1 P21554 1/20 0.48
▸ POLB P06746 2/20 0.48
▸ CTDSP1 Q9GZU7 1/20 0.47
▸ ALDH1A1 P00352 5/20 0.47
▸ USP2 O75604 2/20 0.47
▸ TSHR P16473 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24124800 0.89 MAPT (0.62) MAPTSMN1; SMN2HTTMEN1KMT2A
SCHEMBL24125084 0.88 MAPT (0.61) MAPTSMN1; SMN2HTTMEN1KMT2A
SCHEMBL25921176 0.88 CNR2 (0.52) MAPTSMN1; SMN2HTTMEN1KMT2A
SCHEMBL25921173 0.86 MAPT (0.53) MAPTSMN1; SMN2HTTMEN1KMT2A
SCHEMBL30270587 0.86 CYP1A2 (0.58) MAPTSMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL25921866 0.86 CYP1A2 (0.58) MAPTSMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL25922340 0.79 CTDSP1 (0.64) MAPTMEN1KMT2AMAPK1LMNA
SCHEMBL24124186 0.78 MAPT (0.57) MAPTSMN1; SMN2HTTMEN1KMT2A
SCHEMBL24124898 0.78 MAPT (0.57) MAPTSMN1; SMN2HTTMEN1KMT2A
SCHEMBL25922077 0.78 MAPT (0.56) MAPTSMN1; SMN2HTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 MAPT 4492/4885SMN1; SMN2 4270/4885HTT 4222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback